TELA Bio shareholders approve 3.5M share equity plan increase, elect three directors

TELA Bio, Inc.

Stockholders approved 3,500,000 share increase to 2019 Equity Incentive Plan; total authorized shares now 10,932,620.
Joseph Capper, Betty Jo Rocchio, and William Plovanic elected as Class I directors until 2029.
KPMG LLP ratified as independent auditor for fiscal 2026 with 33.4M votes for, 17,890 against.
Non-binding advisory vote on named executive officer compensation passed: 20.9M for, 6.9M against.
Plan amendment prohibits repricing of options/SARs without stockholder approval and extends plan term to 10 years from April 8, 2026.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

TELA Bio, Inc. shareholders approved Election of Class I Directors at the 2026-04-24 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-04-24

Exact text from the filing

Proposal 1 - Election of Class I Directors . Each of Joseph Capper, Betty Jo Rocchio and William Plovanic were elected to the Board to serve as Class I directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Joseph Capper 27,244,482 567,207 5,650,509 Betty Jo Rocchio 27,595,955 215,734 5,650,509 William Plovanic 27,497,453 314,236 5,650,509

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

TELA Bio, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. at the 2026-04-24 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-04-24

Exact text from the filing

Proposal 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as follows: Votes For Votes Against Abstentions Broker Non-Votes 20,891,695 6,900,032 19,962 5,650,509

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

TELA Bio, Inc. shareholders approved Approval of an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase the authorized shares issuable thereunder by 3,500,000 shares. at the 2026-04-24 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-04-24

Exact text from the filing

Proposal 4 - Approval of an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase the authorized shares issuable thereunder by 3,500,000 shares. The Plan Amendment was approved, as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,256,266 538,830 16,593 5,650,509

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-072931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.